The inhibition of the hERG1 (encoded by the human ether-a-go-go gene) potassium channel, which is primarily expressed in the heart, is a significant safety concern for drug development, as it can lead to long QT syndrome and potentially fatal cardiac arrhythmias. This evidence concerns the gene KCNH2 and cardiac rhythm disease.